

Board of Directors (in Public)

Item 6.1.2a

Subject: Integrated Performance Committee BAF Key Issues Report
Date of Meeting: 29th November 2023
Presented by: Louise Robson, Chair Integrated Performance Committee
Meeting Held: 23rd October 2023

Agenda Item	Lead Exec	Assurance Received	New/ Emerging Risks	Actions/ Comments
BAF Extract	JM	Overview provided of the Board Assurance Framework in relation to finance and performance risks:	1 risk raised to a 16 in relation to delivery of elective activity due to workforce pressures (including scrub staffing & industrial action)	A range of controls and actions have been identified and continue to be progressed. The Integrated Performance Committee continue deep dive key areas of risk with a residual score of 12 or above as directed by the Executive leads.
IPC SOF Report	JM/KE	IPC SOF report presented and discussed.	Areas of concern have been identified and mitigations in place and recovery plans.	Continued focus on; Theatre scrub staffing, surgery activity, Diagnostics activity (impacting Cancer Performance) and long waiters.
Surgery Activity (scrub vacancies)	JM	Report provided on the current theatre staffing position and forecast to the end of the financial year,	Reduction in number of core theatre lists available to deliver the activity and income plan for the Surgery division.	Mitigating actions have been put in place to manage the risk associated with theatre staffing levels. Updates will be monitored through Operational Board and newly formed staffing group chaired by COO.
Diagnostics (DM01 & FSD)	JM	Update provided on regional FDS performance, CT guided biopsy, EBUS and DMO1	Remains a risk to Cancer performance and delays within pathways in the Trust Ongoing mutual aid to LUFT to equalise wait times in C&M	Ongoing actions monitored through Cancer Board and Weekly Performance
Safer Waiting List	JM	Update provided on the progress delivered by the Safe Waiting List Management group and associated workstreams.	A number of areas have been identified that require further development to ensure that the Trust is processing patients through its waiting list in an effective and safe manner, reducing risk	The Safer Waiting List Group provides assurance to the Trusts Operational Board to ensure identified risks are effectively managed and that all works are planned and carried out in a structured and joined up manner.

Agenda Item	Lead Exec	Assurance Received	New/ Emerging Risks	Actions/ Comments
			and ensuring escalation processes are in place.	
Finance report including CIP & Forecasting	KE	The financial performance for the first 2 quarters is a surplus of £4,938k. This represents a £26k positive variance to plan.	The key risks to achieving the plan are undelivered CIP, achieving the activity plans in elective care and the risks associated with inflation.	FPG will continue to monitor financial performance of Divisions and track CIP delivery.
Capital Report	KE	Update provided on the Trusts progress against the capital plan at the halfway stage of the year, including additions to the plan in respect of Cath Lab 7. Forward look to capital planning for 2024/25 outlined.	-	The Trust has been able to create a contingency in order to respond to risks as they emerge. The capital programme is managed through the work of the Capital Management Group, and the Trust is forecasting to spend all of its capital allocation this year.
Costing Strategy Update	KE	The previous costing strategy focused on improving data quality. Many of the actions have now been completed or superseded. The focus of strategy moving forward now shifts to building engagement and utilising costing outputs to build understanding and aid decision making.	-	Clinical champions and wider involvement from divisional and finance leads will be important to facilitate the next stage of the strategy.
Outcomes of Benchmarking data	KE	Benchmarking contributes to a number of benefits including the mitigation of financial risk, through identification of productivity opportunities and related improvement activities	-	-